Histrelin acetate subcutaneous implant - Endo Pharmaceuticals Solutions

Drug Profile

Histrelin acetate subcutaneous implant - Endo Pharmaceuticals Solutions

Alternative Names: Histrelin implant; LHRH-Hydrogel implant; RL 0903; SPD 424; Supprelin-LA; Vantas; VP 002

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Valera Pharmaceuticals
  • Developer BioPro Pharmaceutical; Endo International; Endo Pharmaceuticals Solutions; Teva-Tuteur; Valera Pharmaceuticals
  • Class Antineoplastics; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precocious puberty
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precocious puberty; Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 23 Mar 2012 No development reported - Preregistration for Prostate cancer in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top